Charles Riv­er bags an­ti­body dis­cov­ery-fo­cused Dis­tri­b­u­tion Bio for $104M, sig­nal­ing re­turn to pre-pan­dem­ic buy­out spree

Charles Riv­er Labs, one of the biggest CROs that spe­cial­izes in pre­clin­i­cal re­search pro­grams, has inked a new dis­cov­ery pact as part of a string of deals over the last few years. And af­ter the Covid-19 pan­dem­ic proved less of a fi­nan­cial bur­den than ex­pect­ed, the com­pa­ny could be ready to make even more moves.

Charles Riv­er $CRL pur­chased an­ti­body dis­cov­ery com­pa­ny Dis­trib­uted Bio for up to $104 mil­lion, the com­pa­nies an­nounced Mon­day, a fig­ure that in­cludes $83 mil­lion in up­front cash. The oth­er $21 mil­lion in the deal is re­served for fu­ture “per­for­mance” pay­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER